DSM-Firmenich AG (VIE:DSFI)
Austria · Delayed Price · Currency is EUR | Market Cap | 16.08B -30.6% |
| Revenue (ttm) | 9.03B -28.5% |
| Net Income | -1.11B |
| EPS | -4.27 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 18.97 |
| Dividend | 2.50 (3.88%) |
| Ex-Dividend Date | May 11, 2026 |
| Volume | n/a |
| Average Volume | 10 |
| Open | 64.02 |
| Previous Close | 64.46 |
| Day's Range | 64.02 - 64.40 |
| 52-Week Range | 55.36 - 99.84 |
| Beta | n/a |
| RSI | 58.79 |
| Earnings Date | Jul 30, 2026 |
About DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and s... [Read more]
Financial Performance
Financial StatementsNews
DSM-Firmenich AG Transcript: Investor update
Transformation completed with a focus on specialty, high-margin segments and operational excellence. 2026 guidance is for 2%-4% organic growth, ~20% EBITDA margin, and 11%-12% cash conversion, with targets rising to 4%-6% growth and 22%-23% margin by 2028. Growth is driven by innovation, portfolio tuning, and disciplined capital allocation.
dsm-firmenich outlines action plan at Investor Event to accelerate performance, following completion of transformation
Press Release dsm-firmenich outlines action plan at Investor Event to accelerate performance, following completion of transformation Kaiseraugst (Switzerland), Maastricht (Netherlands), March 12, 2026...
dsm-firmenich announces share repurchase program to cover share plans and reduce capital
Press Release dsm-firmenich announces share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), March 12, 2026 dsm-firmenich, innovators in ...
dsm-firmenich cancels its shares following completion of its €1.08 billion share repurchase program
Press Release dsm-firmenich cancels its shares following completion of its €1.08 billion share repurchase program Kaiseraugst (Switzerland), Maastricht (Netherlands), February 26 2026 dsm-firmenich, i...
dsm-firmenich publishes 2025 Integrated Annual Report
Press Release dsm-firmenich publishes 2025 Integrated Annual Report Kaiseraugst (Switzerland), Maastricht (Netherlands), February 20, 2026 dsm-firmenich today announces the publication of its Integrat...
dsm-firmenich issues €1.5 billion long-term bonds
Press Release dsm-firmenich issues €1.5 billion long-term bonds Kaiseraugst (Switzerland), Maastricht (Netherlands), February 17 2026 dsm-firmenich today announces the successful launch of a €1.5 bill...
DSM-Firmenich AG Earnings Call Transcript: Q4 2025
Divestment of ANH refocuses the business on nutrition, health, and beauty, with 3% organic sales growth in 2025 and a resilient EBITDA margin near 20%. Cash conversion remains strong, and midterm targets for growth and margin are unchanged, with an upward revision to the cash target expected.
dsm-firmenich provides preliminary comparative figures following the announced divestment of Animal Nutrition & Health (ANH)
Press Release dsm-firmenich provides preliminary comparative figures following the announced divestment of Animal Nutrition & Health (ANH) Kaiseraugst (Switzerland), Maastricht (Netherlands), February...
DSM-Firmenich AG Transcript: Status update
Divestment of Animal Nutrition & Health to CVC for EUR 2.2 billion enables a focused consumer business, with a 20% retained stake and favorable vitamin supply terms. Share buyback and stable dividend reflect confidence in future cash flow, while restated financials and strategic targets will guide the next phase.
DSM-Firmenich to Sell Animal Nutrition Unit to CVC in $2.6 Billion Deal
The sale to CVC Capital Partners marks the final step in its plan to fully focus on human nutrition, health and beauty.
DSM-Firmenich to sell animal health business to CVC Capital
Chemicals company DSM-Firmenich has agreed to sell its Animal Nutrition & Health business to CVC Capital for an enterprise value of around 2.2 billion euros ($2.6 billion), it said on Monday.
dsm-firmenich announces agreement to divest Animal Nutrition & Health to CVC Capital Partners
Press Release dsm-firmenich announces agreement to divest Animal Nutrition & Health to CVC Capital Partners Kaiseraugst (Switzerland), Maastricht (Netherlands), February 9, 2026 dsm-firmenich, innovat...
dsm-firmenich appoints Nikeisha van Sleeuwen as Chief Human Resources Officer
Press Release dsm-firmenich appoints Nikeisha van Sleeuwen as Chief Human Resources Officer Kaiseraugst (Switzerland), Maastricht (Netherlands), January 14, 2026 dsm-firmenich, the leading innovator i...
DSM-Firmenich AG Earnings Call Transcript: Q3 2025
Q3 saw 2% organic sales growth and a 10% adjusted EBITDA increase, with strong margins in core segments despite macro headwinds. Full-year 2025 EBITDA is guided at EUR 2.3 billion, reflecting FX and vitamin price pressures, while strategic synergies and cash performance remain robust.
dsm-firmenich Q3 2025 trading update
Press Release Kaiseraugst (Switzerland), Maastricht (Netherlands), October 30, 2025 dsm-firmenich Q3 2025 trading update Management Report Q3 2025 highlights Solid growth and strong step up in Adjuste...
dsm-firmenich strengthens its Executive Committee for future growth as a consumer-focused company
Press Release dsm-firmenich strengthens its Executive Committee for future growth as a consumer-focused company Kaiseraugst (Switzerland), Maastricht (Netherlands), September 1, 2025 dsm-firmenich is ...
DSM-Firmenich AG Earnings Call Transcript: H1 2025
Delivered 7% organic sales growth and margin improvement in H1 2025, driven by strong performance in core segments and successful synergy realization. Outlook for 2025 EBITDA remains around €2.4 billion, with FX volatility as the main risk.
dsm-firmenich reports H1 2025 results
Press Release Kaiseraugst (Switzerland), Maastricht (Netherlands), July 31, 2025 dsm-firmenich reports H1 2025 results Management Report H1 2025 highlights Good first half of the year, with good organ...
Dsm-firmenich's animal feed unit sale attracts three final bidders, Dutch paper reports
Dsm-firmenich's is close to selling its animal nutrition business, with final bids expected from private equity firms CVC , Apollo and Dutch rival Nutreco, Dutch newspaper Financieele Dagblad reported...
dsm-firmenich announces redemption of €750 million hybrid bond
Press Release dsm-firmenich announces redemption of € 750 million hybrid bond Kaiseraugst (Switzerland), Maastricht (Netherlands), July 1, 2025 dsm-firmenich, innovators in nutrition, health, and beau...
dsm-firmenich announces increase in share repurchase program to reduce capital to €1 billion
Press Release dsm-firmenich announces increase in share repurchase program to reduce capital to €1 billion Kaiseraugst (Switzerland), Maastricht (Netherlands), June 27, 2025 dsm-firmenich, innovators ...
dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion
Press Release dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion Kaiseraugst (Switzerland), Maastricht (Netherlands), June 2, 2025 dsm-firmenich, innovato...
dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2025
Press Release dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2025 Kaiseraugst (Switzerland), Maastricht (Netherlands), May 6, 2025 dsm-firmenich, innovators in nutrition,...
DSM-Firmenich AG Earnings Call Transcript: Q1 2025
Q1 2025 delivered 8% organic growth and a 40% EBITDA increase, driven by strong core business performance and a temporary vitamin impact. Strategic divestments, a €1 billion share buyback, and a €750 million bond strengthened the balance sheet, with full-year EBITDA guidance maintained at €2.4 billion.
Laetitia Pictet appointed Chief Legal, Risk and Compliance Officer of dsm-firmenich
Press Release Laetitia Pictet appointed Chief Legal, Risk and Compliance Officer of dsm-firmenich Kaiseraugst (Switzerland), Maastricht (Netherlands), April 8, 2025 dsm-firmenich, innovators in nutrit...